Back to search results

Observational Study on Transposable Elements in Sepsis

This study is looking at how 'transposable elements' (pieces of DNA that can move around in our genes) might affect people with sepsis. Researchers want to see if these elements make the immune system age faster, increase the risk of death, or lead to more infections in patients with sepsis in the ICU (Intensive Care Unit). You could join if you are 18 or older and admitted to the ICU with sepsis. The study will measure 'immune aging' (how old your immune system appears) at 6 weeks. The current recruitment status is unclear.

Study design
This is an observational study, meaning participants will be monitored without receiving new treatments. It plans to enroll 116 participants.
What's involved
Participants will have blood drawn but will not undergo any additional procedures or interventions.
Compensation
Not stated in the trial record.
Follow-up
Immune aging will be measured at 6 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06809868

Role of Transposable Elements in Septic Immune Aging

Recruiting
Not specifiedAges 18+Observational
University of California, San Francisco
~116 participants
Updated 2026-01-30 on ClinicalTrials.gov
What's tested:RNA and DNA Sequencing

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Immune Aging
Measured over 6 weeks

Conditions

Sepsis
Sepsis and Septic Shock
Sepsis With Multiple Organ Dysfunction (MOD)
Sepsis With Acute Organ Dysfunction
Sepsis, Severe
Sepsis at Intensive Care Unit
Sepsis, Severe Sepsis and Septic Shock
Sepsis, Septic Shock

Explore related trials

Septicemia

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Alexendar R Perez, M.D., Ph.D · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
  • Judith Hellman, M.D. · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
  • Matthieu Legrand, M.D., Ph.D · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

Alexendar R Perez, M.D., Ph.D
[email protected]
415-476-1000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 or older
Admitted to ICU with sepsis (Sepsis 3 Criteria)
SOFA score of at least 2 at time of enrollment

Exclusion

Patients on organ transplantation immunosuppression
Patients with preexisting leukopenia
Cancer patients receiving CAR-T therapy
Patients who are under 18 years of age or otherwise deemed pediatric
Patients with an ongoing bleeding diathesis (ie: DIC, hemorrhagic shock)
Patients with a chronic hemoglobin below 7.0
Patients who, prior to their ICU admission, are blood transfusion dependent

What this trial measures

  • Immune Aging6 weeks